DDInter1323 DDInter557
Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threatening disease requiring life-long management. Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone. Additionally, it is used for the treatment of acromegaly and symptoms arising from various tumors, including carcinoid tumors and vasoactive intestinal tumors (VIPomas). In the past, octreotide has been administered solely by injection. On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance
A 9,10alpha-dihydro derivative of [ergotamine]. Dihydroergotamine is used as an abortive therapy for migraines. Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity. The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution formulated at 75% of the strength of the existing intranasal product.
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ergotamine
Ergotamine {u} (Compound) resembles {v} (Compound) Dihydroergotamine
Octreotide {u} (Compound) causes {v} (Side Effect) Injury
Injury {u} (Side Effect) is caused by {v} (Compound) Dihydroergotamine
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ergotamine
Ergotamine {u} (Compound) resembles {v} (Compound) Ergoloid mesylate
Ergoloid mesylate {u} (Compound) resembles {v} (Compound) Dihydroergotamine
Octreotide {u} (Compound) causes {v} (Side Effect) Anorexia
Anorexia {u} (Side Effect) is caused by {v} (Compound) Bromocriptine
Bromocriptine {u} (Compound) resembles {v} (Compound) Dihydroergotamine
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methylergometrine
Methylergometrine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} (Compound) resembles {v} (Compound) Dihydroergotamine
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ergotamine
Ergotamine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Dihydroergotamine
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methylergometrine
Methylergometrine {u} (Compound) palliates {v} (Disease) migraine
migraine {u} (Disease) is palliated by {v} (Compound) Dihydroergotamine
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methylergometrine
Methylergometrine {u} (Compound) causes {v} (Side Effect) Ventricular fibrillation
Ventricular fibrillation {u} (Side Effect) is caused by {v} (Compound) Dihydroergotamine
Octreotide {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Bexarotene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ergotamine
Ergotamine {u} (Compound) resembles {v} (Compound) Dihydroergotamine
Octreotide {u} (Compound) resembles {v} (Compound) Pasireotide
Pasireotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ergotamine
Ergotamine {u} (Compound) resembles {v} (Compound) Dihydroergotamine
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Ergotamine and Ergotamine (Compound) resembles Dihydroergotamine (Compound)
Octreotide (Compound) causes Injury (Side Effect) and Injury (Side Effect) is caused by Dihydroergotamine (Compound)
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Ergotamine and Ergotamine (Compound) resembles Ergoloid mesylate (Compound) and Ergoloid mesylate (Compound) resembles Dihydroergotamine (Compound)
Octreotide (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Bromocriptine (Compound) and Bromocriptine (Compound) resembles Dihydroergotamine (Compound)
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Methylergometrine and Methylergometrine (Compound) resembles Ergotamine (Compound) and Ergotamine (Compound) resembles Dihydroergotamine (Compound)
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Ergotamine and Ergotamine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dihydroergotamine (Compound)
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Methylergometrine and Methylergometrine (Compound) palliates migraine (Disease) and migraine (Disease) is palliated by Dihydroergotamine (Compound)
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Methylergometrine and Methylergometrine (Compound) causes Ventricular fibrillation (Side Effect) and Ventricular fibrillation (Side Effect) is caused by Dihydroergotamine (Compound)
Octreotide may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Ergotamine and Ergotamine (Compound) resembles Dihydroergotamine (Compound)
Octreotide (Compound) resembles Pasireotide (Compound) and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Ergotamine and Ergotamine (Compound) resembles Dihydroergotamine (Compound)